JP2016106149A5 - - Google Patents

Download PDF

Info

Publication number
JP2016106149A5
JP2016106149A5 JP2016051146A JP2016051146A JP2016106149A5 JP 2016106149 A5 JP2016106149 A5 JP 2016106149A5 JP 2016051146 A JP2016051146 A JP 2016051146A JP 2016051146 A JP2016051146 A JP 2016051146A JP 2016106149 A5 JP2016106149 A5 JP 2016106149A5
Authority
JP
Japan
Prior art keywords
formula
pharmaceutically acceptable
acceptable salt
hepatitis
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016051146A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016106149A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016106149A publication Critical patent/JP2016106149A/ja
Publication of JP2016106149A5 publication Critical patent/JP2016106149A5/ja
Pending legal-status Critical Current

Links

JP2016051146A 2010-11-17 2016-03-15 抗ウイルス化合物 Pending JP2016106149A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41481810P 2010-11-17 2010-11-17
US61/414,818 2010-11-17
US201161504924P 2011-07-06 2011-07-06
US61/504,924 2011-07-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2013539970A Division JP5905020B2 (ja) 2010-11-17 2011-11-16 抗ウイルス化合物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017240524A Division JP2018039851A (ja) 2010-11-17 2017-12-15 抗ウイルス化合物

Publications (2)

Publication Number Publication Date
JP2016106149A JP2016106149A (ja) 2016-06-16
JP2016106149A5 true JP2016106149A5 (enExample) 2016-10-20

Family

ID=45099196

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2013539970A Active JP5905020B2 (ja) 2010-11-17 2011-11-16 抗ウイルス化合物
JP2016051146A Pending JP2016106149A (ja) 2010-11-17 2016-03-15 抗ウイルス化合物
JP2017240524A Withdrawn JP2018039851A (ja) 2010-11-17 2017-12-15 抗ウイルス化合物
JP2019206819A Withdrawn JP2020037584A (ja) 2010-11-17 2019-11-15 抗ウイルス化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2013539970A Active JP5905020B2 (ja) 2010-11-17 2011-11-16 抗ウイルス化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017240524A Withdrawn JP2018039851A (ja) 2010-11-17 2017-12-15 抗ウイルス化合物
JP2019206819A Withdrawn JP2020037584A (ja) 2010-11-17 2019-11-15 抗ウイルス化合物

Country Status (18)

Country Link
US (3) US9156823B2 (enExample)
EP (3) EP2640719B1 (enExample)
JP (4) JP5905020B2 (enExample)
KR (5) KR101835474B1 (enExample)
AR (1) AR083711A1 (enExample)
AU (3) AU2011328980B2 (enExample)
CA (3) CA3095528C (enExample)
ES (1) ES2634095T3 (enExample)
HK (1) HK1250162A1 (enExample)
IL (1) IL226346A (enExample)
NZ (2) NZ710567A (enExample)
PL (1) PL2640719T3 (enExample)
PT (1) PT2640719T (enExample)
SG (2) SG10201509456SA (enExample)
SI (1) SI2640719T1 (enExample)
TW (3) TWI640526B (enExample)
UY (1) UY33735A (enExample)
WO (1) WO2012068234A2 (enExample)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE029877T2 (en) 2003-05-30 2017-04-28 Gilead Pharmasset Llc Modified fluorinated nucleoside analogues
HUE030465T2 (hu) 2009-05-13 2017-05-29 Antivirális vegyületek
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
EA020031B1 (ru) 2009-06-11 2014-08-29 Эббви Бахамаз Лтд. Противовирусные соединения
US20130296311A1 (en) * 2010-05-28 2013-11-07 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
NZ710567A (en) 2010-11-17 2017-01-27 Gilead Sciences Inc Antiviral compounds
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
EP2709613B2 (en) 2011-09-16 2020-08-12 Gilead Pharmasset LLC Methods for treating hcv
CN105837584B (zh) 2011-11-16 2018-07-13 吉利德制药有限责任公司 作为抗病毒化合物的缩合的咪唑基咪唑
AU2015252077A1 (en) * 2011-11-16 2015-11-19 Gilead Pharmasset Llc Antiviral compounds
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2013217224B2 (en) * 2012-02-10 2017-04-06 Lupin Limited Antiviral compounds with a dibenzooxaheterocycle moiety
US20130309196A1 (en) * 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
US9079887B2 (en) * 2012-05-16 2015-07-14 Gilead Sciences, Inc. Antiviral compounds
US9233974B2 (en) * 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
EP2950786B1 (en) 2013-01-31 2019-11-27 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
JP5614568B1 (ja) * 2013-02-07 2014-10-29 保土谷化学工業株式会社 ジアザトリフェニレン環構造を有する化合物および有機エレクトロルミネッセンス素子
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
WO2014185995A1 (en) * 2013-05-16 2014-11-20 Gilead Pharmasset Llc Hepatitis c treatments with sofosbuvir
CN104211677B (zh) * 2013-05-30 2018-02-23 浙江九洲药业股份有限公司 一种抗丙型肝炎药物中间体的制备方法
CN104211565A (zh) * 2013-05-31 2014-12-17 浙江九洲药业股份有限公司 一种抗丙型肝炎药物中间体的制备方法
WO2014206257A1 (zh) 2013-06-26 2014-12-31 浙江九洲药业股份有限公司 一种2-羧酸吡咯烷衍生物的制备方法
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
PT3038601T (pt) * 2013-08-27 2020-06-30 Gilead Pharmasset Llc Formulação combinada de dois compostos antivirais
US20150064252A1 (en) * 2013-08-27 2015-03-05 Gilead Pharmasset Llc Solid dispersion formulation of an antiviral compound
CN104418784B (zh) * 2013-09-04 2019-02-19 浙江九洲药业股份有限公司 一种抗病毒药物中间体的拆分方法
WO2015089810A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Fused tetracyclic heterocyclic compounds and methods of use thereof for the treatment of viral diseases
US9512108B2 (en) 2013-12-31 2016-12-06 Nanjing Sanhome Pharmaceutical Co., Ltd. 9,9,10,10-Tetrafluoro-9,10-dihydrophenanthrene hepatitis C virus inhibitor and application thereof
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
WO2015184644A1 (zh) * 2014-06-06 2015-12-10 爱博新药研发(上海)有限公司 抑制丙肝病毒的化合物、药物组合物及其应用
TWI721947B (zh) * 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
TW202014413A (zh) 2014-06-11 2020-04-16 美商基利法瑪席特有限責任公司 製備抗病毒化合物之方法
WO2015191526A2 (en) * 2014-06-12 2015-12-17 Gilead Sciences, Inc. Antiviral compounds
JP7381190B2 (ja) 2014-12-26 2023-11-15 エモリー・ユニバーシテイ Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
CN104592124B (zh) * 2015-01-04 2018-01-02 华南理工大学 一种萘[1,2]并咪唑双极性共轭化合物及制备与应用
WO2016141890A1 (en) * 2015-03-12 2016-09-15 Sunshine Lake Pharma Co., Ltd. Compounds as hepatitis c virus inhibitors and pharmaceutical uses thereof
WO2016202232A1 (zh) * 2015-06-19 2016-12-22 重庆博腾制药科技股份有限公司 一种(4S)-N-Boc-4-甲氧基甲基-L-脯氨酸胺盐的合成方法
CN106256819B (zh) * 2015-06-19 2019-07-09 重庆博腾制药科技股份有限公司 一种(4S)-N-Boc-4-甲氧基甲基-L-脯氨酸胺盐的合成方法
WO2017023631A1 (en) 2015-08-06 2017-02-09 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
KR101919194B1 (ko) * 2015-09-15 2018-11-15 주식회사 엘지화학 헤테로고리 화합물 및 이를 포함하는 유기 발광 소자
WO2017181383A1 (en) * 2016-04-21 2017-10-26 Merck Sharp & Dohme Corp. Hepatitis c virus inhibitors
ES2990061T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros espirocíclicos para la degradación de proteínas diana
EP3454856B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
EA201892375A1 (ru) 2016-05-27 2019-08-30 Джилид Сайэнс, Инк. Способы лечения инфекций, вызываемых вирусом гепатита b
CN106432197B (zh) * 2016-09-07 2019-12-10 上海众强药业有限公司 一种雷迪帕韦中间体单对甲苯磺酸盐、其晶型及其制备方法
CN107674062B (zh) * 2016-11-30 2020-03-27 上海博志研新药物技术有限公司 抗丙肝药物中间体、制备方法及应用
WO2018138050A1 (de) 2017-01-26 2018-08-02 Bayer Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
PT3706762T (pt) 2017-12-07 2024-12-05 Univ Emory N4-hidroxicitidina e derivados e utilizações antivirais relacionadas com os mesmos
CR20200347A (es) 2018-02-13 2020-09-23 Gilead Sciences Inc Inhibidores pd-1/pd-l1
TWI712412B (zh) 2018-04-19 2020-12-11 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
KR20210042264A (ko) 2018-05-15 2021-04-19 유니버시티 오브 루이빌 리서치 파운데이션, 인코포레이티드 요법에서의 사용을 위한 우롤리틴 a 및 그의 유도체
SG11202012425QA (en) 2018-07-13 2021-01-28 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
KR102316919B1 (ko) 2019-11-28 2021-10-22 서울시립대학교 산학협력단 피지컬 컴퓨팅 소프트웨어를 이용한 코딩 교육 교재 및 이를 활용한 코딩 교육 방법
CN111018870B (zh) * 2019-11-29 2021-07-23 南京正济医药研究有限公司 一种维帕他韦中间体的制备方法
CN115210229A (zh) 2020-01-03 2022-10-18 博格有限责任公司 多环酰胺作为治疗癌症的ube2k调节剂
WO2021174167A1 (en) * 2020-02-28 2021-09-02 Remix Therapeutics Inc. Compounds and methods for modulating splicing
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
CN112877379B (zh) * 2021-01-18 2023-09-01 华南理工大学 一种化学酶法合成n-[(3r,6r)-6-甲基哌啶-3-基]氨基甲酸叔丁酯的方法
US12497408B2 (en) * 2021-05-21 2025-12-16 Gilead Sciences, Inc. Tetracyclic compounds and methods for the treatment of Zika virus infection
US12037340B2 (en) 2021-05-21 2024-07-16 Gilead Sciences, Inc. Pentacyclic derivatives as Zika virus inhibitors

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
EP0533833B1 (en) 1990-06-13 1995-12-20 GLAZIER, Arnold Phosphorous produgs
EP0481214B1 (en) 1990-09-14 1998-06-24 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Prodrugs of phosphonates
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
US5858389A (en) 1996-08-28 1999-01-12 Shaker H. Elsherbini Squalene is an antiviral compound for treating hepatitis C virus carriers
CA2448737C (en) 2001-07-20 2010-06-01 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
DK1625154T3 (da) 2003-05-09 2014-02-24 Boehringer Ingelheim Int Hepatitis c virus ns5b-polymeraseinhibitor-bindende lomme
US7157492B2 (en) 2004-02-26 2007-01-02 Wyeth Dibenzo chromene derivatives and their use as ERβ selective ligands
RS51974B (sr) 2004-07-16 2012-02-29 Gilead Sciences Inc. Antivirusna jedinjenja
CN101160324B (zh) * 2005-02-18 2013-04-24 米德列斯公司 缺乏岩藻糖残基的抗前列腺特异性膜抗原(psma)单克隆抗体
US8891379B2 (en) 2006-06-02 2014-11-18 Riverbed Technology, Inc. Traffic flow inference based on link loads and gravity measures
US7759495B2 (en) * 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) * 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JPWO2008069262A1 (ja) 2006-12-07 2010-03-25 第一三共株式会社 安定性が改善されたフィルムコーティング製剤
US7741347B2 (en) 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
DK2250163T3 (da) * 2008-02-12 2012-07-16 Bristol Myers Squibb Co Hepatitis C-virusinhibitorer
US8147818B2 (en) * 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2009102325A1 (en) * 2008-02-13 2009-08-20 Bristol-Myers Squibb Company Imidazolyl biphenyl imidazoles as hepatitis c virus inhibitors
US7704992B2 (en) 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20100256184A1 (en) 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US8729077B2 (en) * 2008-11-28 2014-05-20 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
CA2750577A1 (en) * 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
US20120040977A1 (en) * 2009-02-23 2012-02-16 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
RU2544010C2 (ru) * 2009-02-27 2015-03-10 Энанта Фармасьютикалс, Инк. Ингибиторы вируса гепатита с
SG174883A1 (en) 2009-03-27 2011-11-28 Presidio Pharmaceuticals Inc Fused ring inhibitors of hepatitis c
US8709999B2 (en) 2009-03-27 2014-04-29 Presidio Pharmaceuticals, Inc. Substituted bicyclic HCV inhibitors
EP2430015B1 (en) 2009-05-12 2015-06-17 Merck Sharp & Dohme Corp. Fused tricyclic compounds useful for the treatment of viral diseases
HUE030465T2 (hu) * 2009-05-13 2017-05-29 Antivirális vegyületek
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8138215B2 (en) * 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102480971B (zh) * 2009-09-04 2014-11-26 杨森制药公司 化合物
US9156818B2 (en) * 2009-09-11 2015-10-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
EP2503881B1 (en) 2009-11-25 2015-05-13 Merck Sharp & Dohme Corp. Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
US8377980B2 (en) * 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20110152246A1 (en) 2009-12-18 2011-06-23 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
AU2010341537A1 (en) * 2009-12-22 2012-08-09 Merck Sharp & Dohme Corp. Fused Tricyclic Compounds and methods of use thereof for the treatment of viral diseases
EP2545060B1 (en) 2010-03-09 2015-11-25 Merck Sharp & Dohme Corp. Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
US9125904B1 (en) * 2010-05-11 2015-09-08 Achillion Pharmaceuticals, Inc. Biphenyl imidazoles and related compounds useful for treating HCV infections
US20110312996A1 (en) 2010-05-17 2011-12-22 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
US8859595B2 (en) * 2010-08-26 2014-10-14 Rfs Pharma, Llc Potent and selective inhibitors of hepatitis C virus
WO2012048421A1 (en) 2010-10-14 2012-04-19 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
NZ710567A (en) 2010-11-17 2017-01-27 Gilead Sciences Inc Antiviral compounds
WO2012087976A2 (en) 2010-12-21 2012-06-28 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
CN105837584B (zh) 2011-11-16 2018-07-13 吉利德制药有限责任公司 作为抗病毒化合物的缩合的咪唑基咪唑
US9079887B2 (en) * 2012-05-16 2015-07-14 Gilead Sciences, Inc. Antiviral compounds
US20130309196A1 (en) 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
US20150064252A1 (en) 2013-08-27 2015-03-05 Gilead Pharmasset Llc Solid dispersion formulation of an antiviral compound
PT3038601T (pt) 2013-08-27 2020-06-30 Gilead Pharmasset Llc Formulação combinada de dois compostos antivirais
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
TW202014413A (zh) 2014-06-11 2020-04-16 美商基利法瑪席特有限責任公司 製備抗病毒化合物之方法
JP2016051146A (ja) 2014-09-02 2016-04-11 ウシオ電機株式会社 光検出装置

Similar Documents

Publication Publication Date Title
JP2016106149A5 (enExample)
JP2017186358A5 (enExample)
JP2014507446A5 (enExample)
JP2018024670A5 (enExample)
JP2017105793A5 (enExample)
HRP20230274T1 (hr) Kemijski spojevi
JP2016034978A5 (enExample)
JP2019524883A5 (enExample)
JP2020097577A5 (enExample)
JP2015078230A5 (enExample)
JP2018048154A5 (enExample)
JP2012532874A5 (enExample)
JP2016539157A5 (enExample)
JP2018521020A5 (enExample)
JP2017533930A5 (enExample)
JP2016522254A5 (enExample)
EA201890654A1 (ru) Терапевтические композиции для лечения вируса иммунодефицита человека
JP2018501215A5 (enExample)
JP2016540015A5 (enExample)
JP2015516419A5 (enExample)
JP2017522300A5 (enExample)
JP2019529514A5 (enExample)
HRP20191121T1 (hr) Tretman multiple skleroze
JP2016532632A5 (enExample)
IL312635A (en) Pharmaceutical combinations for treatment of hbv